This Phase 2 study tests whether adding leronlimab to standard chemotherapy and a targeted drug can shrink tumors or improve survival in people with a specific type of advanced colorectal cancer (MSS mCRC) that has not responded to prior treatments. About 66 adults will receive o…
Phase: PHASE2 • Sponsor: CytoDyn, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC